Empower Clinics Inc (CSE:CBDT) (OTCQB:EPWCF) announced Wednesday that it has initiated phases one and two of coronavirus (COVID-19) testing at its clinic in Portland, Oregon.
As reported in April, the life sciences group has established a four-phase antibody testing program using its RAPID COVID-19 test kits.
“Our team has performed COVID-19 tests for groups and individuals both remotely and inside our clinics as part of our testing program,” CEO Steven McAuley said in a statement. “With national rates of COVID-19 currently spiking, it is critical that we expand our testing services to our large patient base in Oregon.”
READ: Empower Clinics reaches third stage of its four-phase national roll-out of coronavirus testing
Additionally, Empower said it is collecting signatures at the Portland clinic in support of a proposed state ballot initiative that would create a licensed and supervised-psilocybin-assisted therapy system.
The measure, IP34, requires 145,000 signatures to appear on the ballot in November. So far it has gathered 142,480, according to yesonIP34.org.
In May, Empower launched Dosed Wellness, a psychedelics division leveraging the company’s network of physicians and clinics, research opportunities and a base of more than 165,000 patients.
“A major aspect of our new psychedelics division, Dosed Wellness, is assisting in the development of new legal markets from the ground up,” Dustin Klein, Empower senior vice president of Business Development said.
“We are so pleased that our Portland clinic is a safe location to collect signatures for Oregon’s IP34 ballot initiative.”
The Vancouver-based company pointed to studies at institutions such as Johns Hopkins, UCLA, and NYU that have shown that psilocybin is uniquely effective in treating depression, anxiety, trauma like PTSD and addiction.
Contact Andrew Kessel at [email protected]
Follow him on Twitter @andrew_kessel